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University of California
This meeting, a joint event of Cold Spring Harbor 
Labora tory (CSHL) and the Wellcome Trust and funded 
in part by the National Institute of General Medical 
Sciences (NIGMS), brings together scientists from many 
disciplines, from basic genomics to clinical medicine. 
They share a common interest in understanding the role 
of inherited variation in drug response phenotypes 
ranging from life threatening adverse drug reactions 
(ADRs) to lack of the desired therapeutic drug effect. 
Pharmacogenomics is a major component of the 
movement toward personalized or individualized medi­
cine. This year, in addition to prominent examples of 
pharmacogenomic research, the meeting heard contribu­
tions on state­of­the­art next­generation sequencing, 
genome­wide analyses, genetic control of expression, 
epigenetics, and translational bioinformatics, comple men­
ted by presentations on ethical, legal, and societal issues. 
There were more than 130 international participants.
Future scope of genomic medicine and key 
discoveries in pharmacogenomics
The keynote lectures of the opening sessions were 
dedicated to the exploration of the future potential of 
pharmacogenomic applications in health care based on 
past and current developments. Eric D Green, Director of 
the National Human Genome Research Institute 
(NHGRI, Bethesda, USA), laid out the opportunities of 
the human genome sequence for genomic medicine 
(described as ‘from base pairs to bedside’). The path of 
realization faces bottlenecks at many levels, but these can 
be overcome using techniques including functional 
genomic analysis (such as comparative genome sequencing 
and epigenetic landscaping), elucidation of human 
genomic variation (such as the HapMap Project and the 
1000 Genomes Project), and identification of the genomic 
basis for rare monogenetic and common complex human 
disease (such as genome­wide association studies 
(GWASs) and post­GWAS approaches). Because the 
costs have become affordable, we can now perform 
routine whole­genome sequencing of individual human 
genomes. Yet the next­generation sequencing techniques 
will produce enormous amounts of sequence data that 
will require complex computational analyses and 
thorough interpretation of genomic information. Green 
presented a strategic plan of breaking down the tasks into 
five genomic domains, which will aid efforts to overcome 
current and future bottlenecks (Figure  1). For timely 
progress, this strategic plan should be revisited and 
refined every 5 years.
Pharmacogenetic markers and how they were dis­
covered were presented by Michel Eichelbaum (Dr 
Margarete Fischer­Bosch­Institute of Clinical Pharma­
cology, Stuttgart, Germany). He highlighted prominent 
examples following a historic tour from the first 
pharmaco genetic trait at the beginning of the era of 
pharmacogenomics ­ the observation of the occurrence 
of hemolysis/death in relation to fava bean consumption 
in Mediterranean populations 3,000 years ago and its 
mechanistic explanation in modern times ­ to the 
discovery by Beutler, Waller and Löhr in 1956­7 of 
sensitivity to an antimalarial drug (primaquine) related to 
glucose 6­phosphate dehydrogenase deficiency. Some 
more recent examples are shown in Table 1. In the past 
35 years, characterization of loss of function of drug 
metabolizing enzymes ­ including Eichelbaum’s work on 
the cytochrome P450 (CYP) 2D6 poor metabolizer 
phenotype ­ has led to the understanding of the profound 
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effects of inherited differences in drug metabolizing 
enzymes on the pharmacokinetics of a drug. Such differ­
ences can result in more than a 100­fold difference in 
systemic drug exposure, with clinically important effects 
on drug response. Today, it is recognized that trans­
porters, receptors, and genes of signaling pathways are 
Figure 1. A strategic plan to achieve the goal of genomic medicine (‘base pairs to bedside’). The scheme illustrates past and current 
accomplishments as well as future tasks in the five domains of genomic medicine, also embracing cross cutting elements: bioinformatics 
and computational biology, education and training, and genomics and society. Solid lines indicate major ongoing or expected activities and 
accomplishments across the domains at respective time intervals. Dashed lines indicate fewer activities, respectively.
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Table 1. Examples of implementation of pharmacogenetics for the improvement of drug response and avoidance of 
adverse drug reactions
 Marker and   
Drug genetic variants Treatment application Drug effect and risks
Tamoxifen CYP2D6; PM alleles  Breast cancer Prodrug that requires conversion into active metabolite 
 *3, *4,*5, *6 and *7  (endoxifen); PM patients have a higher risk of developing  
   recurrence than EM patients; CYP2D6 polymorphism explains  
   38 to 69% of variable plasma endoxifen levels
Warfarin CYP2C9; VKORC1  Prevention of thrombo-embolic  Increased risk of thrombo-embolic events at INR <2 to 3;  
  events; maintenance dose is critical  increased risk of bleeding at INR >2 to 3; drug is the largest 
  (INR 2-3) cause of AEs and hospital emergency room visits 
Clopidogrel CYP2C19*2 Cardiovascular medicine to prevent  Increased risk of cardiovascular event; explains 12% of 
  platelet aggregation variability
Abacavir HLA-B*5701 AIDS 5% of patients develop hypersensitivity (fever, skin rash,  
   gastro-intestinal symptoms, or eosinophilia); genotyping  
   before therapy reduces incidence of hypersensitivity and is  
   cost effective
Flucloxacillin,  HLA-B*5701 Bacterial infections; β-lactam 20% of DILI-related hospitalizations 
amoxicillin-clavulanate   antibiotics 
Simvastatin OATP1B1*5 Control of elevated cholesterol  Increased risk of myopathy 
  (hypercholesterolemia)  
Cisplatin TPMT, COMT Chemotherapy  Permanent, bilateral hearing loss (grade 2-4) in 10 to 25% of  
   adult patients and 41 to 61% of children 
AE, adverse event; AIDS, acquired immune deficiency syndrome; COMT, catechol-O-methyl transferase; CYP, cytochrome P450; DILI, drug-induced liver injury; EM, 
extensive metabolizer; HLA-B, human leukocyte antigen B; INR, international normalized ratio; OATP, organic anion transporting polypeptide; PM, poor metabolizer; 
TPMT, thiopurine S-methyltransferase; VKORC, vitamin K, epoxide reductase complex.
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also important pharmacogenomic components. It is now 
understood that genetic factors account for 20 to 95% of 
the variability in drug disposition (that is, absorption, 
distribution, metabolism and excretion) and effects; 
however, pharmacogenomic testing is not about a yes or 
no answer but about probabilities that a response/event 
occurs. Drug effects (response, resistance, and ADRs) 
cannot be explained by single genes or variants but are 
under the influence of multiple genetic and non­genetic 
factors (such as age, sex, body mass index and organ 
function). The identification of clinically useful markers 
therefore requires large pharmacogenomic studies with 
phenotypically well characterized study subjects, 
comprehensive allele coverage for the genetic description 
of these phenotypes, and consideration of confounders 
(such as drug adherence and co­medications).
Innovations in genomic biology and implications 
for pharmacogenomics
Deborah A Nickerson (University of Washington School 
of Medicine, Seattle, USA) highlighted the finding of 
new genetic variants and genetic signatures for diseases 
identified by exome sequencing. The complete set of 
exons (including splice sites and microRNAs) ­ referred 
to as the ‘exome’ ­ makes up only 1% of the human 
genome. By selecting the exome to sequence, important 
information about an individual can be obtained at a 
much lower cost than would be required for sequencing 
their entire genome. Assessment of the results of exome 
sequencing is based on knowledge of the genetic code 
and allows a more informative interpretation of genetic 
variants. Rare variants that typically provide a stronger 
indication of disease susceptibility can be detected. As a 
result of the sequencing of 1,000 exomes more than 
360,000 novel variants have been identified, half of 
which change the resulting amino acid sequences. For 
example, examining CYP2C9 among 1,000 genomes 
revealed considerably more variants than those reported 
in public databases. Some of these result in amino acid 
changes at substrate binding sites, which means that 
exome sequen cing could be highly relevant for 
pharmacogenomics discoveries.
The genetic control of drug response was addressed by 
David B Goldstein (Duke University, Durham, USA) 
using the example of variable response to drug treatment 
(pegylated interferon and ribavirin) of hepatitis C. He 
outlined discovery strategies for pharmacogenomic 
ques tions and reported on the determination of drug 
efficacy by analyzing sustained virological response 
rates. An association between sustained virological 
response and the variant rs12979860 of the interferon 
(IFN)λ­encoding gene IL-28B was identified by GWAS. 
There was inter­ethnic variation in the allele frequency 
of the pro tective reference allele (African Americans < 
Hispanic  < Caucasians < East Asians). Although no 
biological function is known, poor treatment responders 
have higher blood levels of expression of IFN­responsive 
genes. Likewise, GWASs identified an association 
between an ADR (severe anemia) and the chromosome 
20q13 region. A functional interpretation is possible 
through a neighboring gene encoding an enzyme of ATP 
synthesis (ITPA), which contains two functional 
variants. Addressing the implications for diagnostic 
utility, drug development and evaluation, mechanistic 
insights, and control of sources of variability in clinical 
trials, Goldstein emphasized that although many drug 
responses are influenced by genetic variants, they cannot 
always directly be detected by GWASs but require 
further in­depth analysis.
The putative role of the transcriptome for pharmaco­
genomics was addressed by Thomas Gingeras (CSHL). 
He reported that eukaryotic transcriptomes are far from 
being understood because information stored in DNA 
sequences is complex, layered, and compartmentalized. 
Thus, the genome has to be re­annotated because of a 
growing number of newly identified transcripts, not only 
non­coding but also coding. He presented data from the 
Sanger Institute and ENCODE transcriptome projects 
based on deep sequencing and tiling array analyses of 
transcriptomes of various cell lines and tissues of 
multiple organisms. Subfractionation of cells enriches 
for certain RNA groups, resulting in the detection of 
new RNAs and RNA isoforms. The genome can be 
regarded as being much richer than currently thought 
because regions are interconnected and littered with 
start sites, with many functional elements on top of each 
other. Thus, a gene represents a ‘coding/non­coding 
cluster in the genome’, which serves as a template for up 
to eight transcripts. This refined view of unique 
transcriptomes should be applied to gaining a better 
understanding of gene regulation and its possible role in 
disease and drug response.
Copy number variants (CNVs) account for a major 
proportion of human genetic polymorphisms and they 
may have an important role in genetic susceptibility to 
human disease. Peter J Donnelly (Wellcome Trust Centre 
for Human Genetics, Oxford, UK) reported on a large 
genome­wide study of the Wellcome Trust Case Control 
Consortium (WTCCC) for the investigation of 
associations between CNVs and eight common diseases 
(16,000 patients ­ 2,000 with each of bipolar disorder, 
breast cancer, coronary artery disease, Crohn’s disease, 
hypertension, rheumatoid arthritis, type 1 diabetes, and 
type 2 diabetes). They used an array targeting more than 
11,700 CNVs, each detected by ten probes, and only 
3,000 CNVs passed quality control. Although a small 
number of CNVs were found to be associated with 
Crohn’s disease, type 2 diabetes, and breast cancer, these 
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associations had been previously identified by tagging 
SNPs, from which it follows that CNVs cannot explain 
much of the missing heritability of common diseases. 
More over, analytical challenges in CNV studies include 
varying results attributable to different DNA sources 
(blood versus B cell lines) and observed high false­
negative rates from comparative CNV associations 
generated from SNP chips (Affymetrix versus Illumina 
platforms). Thus, CNV findings from case­control studies 
must be interpreted with care.
One of us (ME) explained the role of epigenetics in 
personalized medicine, particularly in oncology. He 
described that the contribution of DNA methylation and 
histone modifications, the two main epigenetic layers, to 
this area could be subdivided into epigenetic markers to 
predict drug sensitivity (pharmacoepigenetics) and 
genetic markers to predict response to epigenetic drugs 
(such as DNA demethylating agents and histone deace­
tylase inhibitors). The best example of pharmacogenetics 
is the prediction of good response to the chemotherapy 
drugs temozolomide and carmustine in gliomas in which 
there is silencing of the DNA repair enzyme O6­
methylguanine­DNA methyltransferase (MGMT) asso­
cia ted with promoter CpG island hypermethylation. 
Further examples included the epigenetic inactivation of 
the Werner gene and response to irinotecan in colorectal 
cancer. Recent results from his group have demonstrated 
that hypermethylation of the BRCA1 breast cancer gene 
CpG island is a marker of good response to poly ADP­
ribose polymerase (PARP) inhibitors in breast cancer 
cells. This finding might significantly increase the number 
of breast cancer patients that could benefit from these 
therapies outside the high­risk inherited forms of the 
disease. He also showed that the genes involved in the 
epigenetic machinery, such as DNA methyltransferases 
and histone modifiers, can also undergo genetic changes 
related to differential sensitivity to epigenetic drugs. 
Examples of genetic amplification, deletion, and mutation 
of these genes are described in the literature, and a 
frameshift mutation in the histone deacetylase 2 
(HDAC2) gene is associated with resistance to histone 
deacetylase inhibitors. Emerging research in the 
genomics and epigenomics arena will provide us with 
new epigenetic candidates for the personalized treatment 
of human malignancies.
The role of bioinformatics in pharmacogenomics
Steven E Brenner (University of California, Berkeley, 
USA) showed the long­term exponential growth of 
sequence data and its recent disruptive increase in 
growth. His experience of RNA splice regulation using 
RNA sequencing technology showed that the majority of 
alternative splicing events contain previously unanno­
tated exonic structures; he extrapolated from this to 
highlight the great potential of using the vast amounts of 
sequence data in the emerging field of pharmaco­
transcriptomics. The talk introduced a community 
experi ment to evaluate computational methods for 
pheno type prediction based on genomic variation (the 
Critical Assessment of Genome Interpretation, CAGI: 
http://genomeinterpretation.org), modeled on the 
Critical Assessment of Structure Prediction (CASP) 
exercise for protein structure prediction. There is an 
urgent need to interpret the multitude of variations in 
expression, allele­specific expression, splicing, transcript 
structure, and common and rare exonic variants. Dozens 
of prediction algorithms exist for this purpose, but their 
utility is not well understood. The CAGI experiment 
presented a number of datasets for the prediction of 
phenotypic consequences, including a pharmacogenomic 
dataset of over 50 breast cancer cell lines exposed to over 
50 different drugs that will be relevant for the prediction 
of drug response. Within the personal genome project 
the genomes of ten individuals are being investigated for 
the prediction of 50 health­ and disease­related 
phenotypes. CAGI ultimately had over 100 prediction 
submissions from seven countries. CAGI aims to under­
stand the diversity of mechanisms of genome variation, 
identify bottlenecks in genome interpretation, inform 
critical areas of future research, and connect researchers 
from diverse disciplines whose expertise is essential to 
methods for genome interpretation.
Ethical, economical and societal aspects of 
pharmacogenomics
The cost­effectiveness of pharmacogenomics with respect 
to challenges and opportunities in an era of decreasing 
test costs was addressed by David L Veenstra (University 
of Washington, Seattle, USA). A stated lack of evidence 
of clinical utility is a frequent reason for health insurers 
to refuse to reimburse patients for pharmacogenomic 
testing. To better assess such evidence, the Evaluation of 
Genomic Applications in Practice and Prevention 
(EGAPP) initiative is developing a systematic process to 
capture the validity and utility of emerging genetic tests 
for clinical practice. A novel approach, comparative 
effectiveness research, aims to ensure that much more 
useful data will be collected (as compared with standard 
clinical trials) and better methods developed for under­
standing the differences in drug effectiveness among 
different patient groups, such as risk­benefit modeling. 
Lastly, the value of conducting additional research should 
be weighed against the cost of conducting such research 
using quantitative value of research analyses.
Future trends in pharmacogenomics
Integrated presentations from pharmacologists and 
human genome biologists highlighted the incredible 
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oppor tunities for pharmacogenomic applications in 
optimizing drug therapy. Rapid advances in genomic 
technologies are being quickly adopted by pharmaco­
genomics researchers and will fuel progress in this area. 
The overarching need for the collection of large numbers 
of well phenotyped drug­treated populations was a 
central theme of most presentations, as were the diffi­
culties associated with identifying appropriate replication 
cohorts. Future advances in human genomics and their 
application to pharmacogenomics are expected to bring 
continued advances to this important area of translational 
medicine.
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